Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Form 144 notice for proposed sale of securities (Rule 144) filed for common stock to be sold on 09/24/2025 on NASDAQ. The notice lists 2,581 shares to be sold with an aggregate market value of $36,108 against 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 01/25/2022. Recent sales by the same person are disclosed: 3,836 shares sold on 08/27/2025 for $53,455.56 and 1,193 shares sold on 08/28/2025 for $16,540.64. The filing includes a seller representation about absence of undisclosed material adverse information. Several issuer and filer identification fields in the form are blank or not provided in the supplied content.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 1,500 common shares through Morgan Stanley Smith Barney on 09/24/2025 with an aggregate market value of $20,520 and 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 05/17/2022. The filing also discloses recent 10b5-1 sales by the same account on 08/27/2025 (1,600 shares, $22,392) and 08/28/2025 (400 shares, $5,600). The filer certifies no undisclosed material adverse information and indicates reliance on established trading procedures where applicable.
Cadrenal Therapeutics, Inc. reported the outcome of its auditor ratification vote on September 24, 2025. The company disclosed vote totals for the Auditor Ratification Proposal showing 1,207,152 votes in favor, 64,913 votes against, 12,681 abstentions and 0 broker non‑votes. The filing lists Steven Zelenkofske and is signed by Quang X. Pham, Chairman and Chief Executive Officer. This item records a routine corporate governance vote approving the company's independent auditor; no financial results, material transactions, or other operational details were included in the provided text.
Cadrenal Therapeutics insider transaction: The company's Chief Financial Officer, Matthew K. Szot, reported two open-market sales of common stock. He sold 1,600 shares on 08/27/2025 at a weighted-average price of $13.995 and sold 400 shares on 08/28/2025 at $14.00. After the first sale he reported beneficial ownership of 31,733 shares and after the second sale 31,333 shares. The Form 4 indicates these were non-derivative dispositions and includes footnotes that the reported prices reflect multiple trades within the stated ranges.
Cadrenal Therapeutics insider sale disclosure: Quang Pham, who serves as CEO and Chairman and is a director and 10% owner, reported open-market sales of the companys common stock on August 27 and August 28, 2025. On August 27 Mr. Pham sold 3,836 shares at a weighted average price of $13.99, reducing his reported direct beneficial ownership to 214,497 shares. On August 28 he sold 1,193 shares at a weighted average price of $13.99, reducing direct beneficial ownership to 213,304 shares. He also reports indirect ownership of 200,000 shares held by The PVBQ Living Trust, for which he is trustee. The filing indicates the transactions were made pursuant to a written plan consistent with Rule 10b5-1 and is signed by an attorney-in-fact on August 29, 2025.
Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 1,193 common shares through Merrill Lynch on 08/28/2025 with an aggregate market value of $16,540.64. The shares were acquired as founders shares on 01/25/2022 from the company. The filing reports 2,046,854 shares outstanding for the class listed. Separately, the document discloses a recent sale by Quang Pham of 3,836 common shares on 08/27/2025 that generated $53,455.56 in gross proceeds. The issuer name and CIK are not provided in the visible content, and the filer contact details are blank.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 declaring a proposed sale of 400 founder shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,572.00. The filing lists 2,046,854 shares outstanding and an approximate sale date of 08/28/2025 on NASDAQ. The shares were acquired as founders shares on 05/17/2022 from the issuer and payment was recorded on the same date. The filing also discloses recent 10b5-1 sales by the same person: 1,600 shares sold on 08/27/2025 for gross proceeds of $22,392.00. The filer affirms compliance statements required under Rule 144 and 10b5-1.
Cadrenal Therapeutics (CVKD) filed a Form 144 to notify a proposed sale of 1,600 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $22,000. The filing shows 2,046,854 shares outstanding, so the notice covers a very small portion of the company’s outstanding stock. The shares were acquired as founders shares on 05/17/2022 and no payment financing arrangements are indicated. The planned approximate sale date is 08/27/2025. The filer reports no securities sold in the prior three months.
Cadrenal Therapeutics, Inc. (CVKD) filed an amended Form 144 disclosing a proposed sale of 3,836 common shares through Merrill Lynch on the NASQ exchange with an approximate aggregate market value of $53,455.56 and 2,046,854 shares outstanding. The shares were acquired on 01/25/2022 in a private placement from the company and were paid in full on that date. The filing reports no securities sold in the past three months for the account and includes the seller's representation that they are not aware of undisclosed material adverse information regarding the issuer.
Cadrenal Therapeutics, Inc. (CVKD) filed an amended Form 144 disclosing a proposed sale of 3,836 common shares through Merrill Lynch on the NASQ exchange with an approximate aggregate market value of $53,455.56 and 2,046,854 shares outstanding. The shares were acquired on 01/25/2022 in a private placement from the company and were paid in full on that date. The filing reports no securities sold in the past three months for the account and includes the seller's representation that they are not aware of undisclosed material adverse information regarding the issuer.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying a proposed sale of 30,600 common shares held by the filer. The shares were acquired in a private placement on 01/25/2022 and the aggregate market value of the shares to be sold is listed as $428,094.00. The form identifies Merrill Lynch (Ponte Vedra Beach, FL) as the broker and lists an approximate sale date of 08/27/2025 on the NASQ exchange. The filing states no securities were sold by the filer in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.